OCUGEN INC. - COMMON STOCK

Ocugen, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial for Gene Therapy Candidate OCU400 to Treat Inherited Retinal Degeneration

01 апр 2022 06:37:00 Источник Nasdaq GlobeNewswire

Ocugen Announces Appointment of Marna C. Whittington, PhD, to Board of Directors

23 мар 2022 06:44:00 Источник Nasdaq GlobeNewswire

Ocugen, Inc. Appoints Jessica Crespo, CPA, to Chief Accounting Officer and Senior Vice President, Finance

21 мар 2022 17:36:00 Источник Nasdaq GlobeNewswire

Ocugen Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

18 мар 2022 16:56:00 Источник Nasdaq GlobeNewswire

Ocugen, Inc. to Present at the 34th Annual ROTH Conference

09 мар 2022 06:11:00 Источник Nasdaq GlobeNewswire

Ocugen Provides an Update on its COVAXIN™ Pediatric (2-18) Emergency Use Authorization (EUA) Request

04 мар 2022 06:01:00 Источник Nasdaq GlobeNewswire

Ocugen Provides Business Update With Fourth Quarter and Full Year 2021 Financial Results

25 фев 2022 06:31:00 Источник Nasdaq GlobeNewswire

Ocugen, Inc. Announces Pricing of $53.5 Million Public Offering of Common Stock

22 фев 2022 20:43:33 Источник Nasdaq GlobeNewswire

Ocugen, Inc. Announces Proposed Public Offering of Common Stock

22 фев 2022 15:02:55 Источник Nasdaq GlobeNewswire

Ocugen to Host Conference Call on Friday, February 25 at 8:30 a.m. ET to Discuss Fourth Quarter and Full Year 2021 Financial Results and Provide Business Update

18 фев 2022 17:12:00 Источник Nasdaq GlobeNewswire